Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The biotech sector, particularly the $XBI ETF, is undergoing changes in its composition and weighting for 2024. The XBI index now includes 137 companies, with around 50% of its value coming from the top 20 companies, each averaging around $50 billion in market cap. Investors are advised on playing swing trades ahead of binary events, selecting quality stocks, and considering various risk vs reward factors such as company pipeline, competition, and management execution.
Has anyone figured out how much the changes made to the weighting of the $XBI on June 21 has affected its performance? Asked another way - is the XBI outperforming bc it's now weighted more heavily towards big biotech?
$XBI Current state of biotech sector- A sector that hasn't done much or most small cap bio stocks remain undervalued not because of lack of clinical development but because of high rate environment. Irony that valuations are mostly depressed despite companies have done well…
In biotech sector, it all boils down to risk vs reward scenarios and some key variables $XBI - company pipeline - competition - overall TAM - development stage - unmet need, no current SOC - market valuation - cash - previous study results And above all- Management execution